Nano-X Imaging Ltd. (NASDAQ: NNOX) (“Nanox”) announced two strategic developments that could reshape how artificial intelligence is deployed in medical imaging. The company has entered an exclusive three-year reseller agreement with Vertec Scientific to distribute HealthOST, its AI-powered software for spinal CT analysis, in the United Kingdom. The deal includes minimum annual license commitments, providing a dedicated UK channel for the technology. HealthOST delivers qualitative and quantitative analysis of spinal CT images, helping clinicians evaluate spinal musculoskeletal diseases such as osteoporosis. This matters because it gives Nanox a commercial foothold in a major market and validates the clinical utility of its AI solutions.
Separately, Nanox.AI has optimized its imaging AI framework for Intel Core Ultra processors using OpenVINO. This optimization demonstrates the potential to run AI inference locally on hospital hardware, reducing reliance on cloud connectivity. For healthcare providers, local inference can mean faster processing, improved data privacy, and lower bandwidth costs. It also allows hospitals with limited or unreliable internet access to benefit from advanced AI tools. Together, these moves support Nanox.AI’s strategy of extracting additional clinical value from already performed scans while expanding commercial reach and offering flexible deployment options.
The UK agreement is particularly significant because it establishes a recurring revenue model through minimum license commitments. It also signals confidence in HealthOST’s ability to address unmet needs in osteoporosis screening. Osteoporosis is often underdiagnosed, and opportunistic screening using existing CT scans could lead to earlier interventions. By partnering with Vertec Scientific, Nanox gains a local partner with established relationships in the UK healthcare system. This could accelerate adoption and pave the way for similar agreements in other regions.
The Intel optimization highlights Nanox’s commitment to making AI accessible and scalable. Running AI locally on hospital hardware eliminates the need to transmit sensitive patient data to the cloud, addressing privacy concerns. It also reduces latency, which is critical for time-sensitive diagnoses. Moreover, it can lower operational costs for hospitals by leveraging existing IT infrastructure. This technical achievement aligns with the broader industry trend toward edge computing in healthcare.
For investors, these developments could enhance Nanox’s competitive position. The company’s integrated platform, which includes Nanox.ARC, Nanox.AI, Nanox.CLOUD, and teleradiology services, aims to drive the transition to preventive care. By expanding market access and improving deployment flexibility, Nanox is addressing two key barriers to AI adoption: distribution and infrastructure. The full article can be viewed at https://ibn.fm/eBRgx. For more information, visit www.Nanox.vision. The latest news and updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX.
These announcements were distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. For full terms of use and disclaimers, see https://www.BioMedWire.com/Disclaimer.
